- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07472582
En chatbot for å redusere chemsex- og HIV-relaterte risikoatferder blant menn som har sex med menn
En chatbot for å redusere chemsex og hiv-relaterte risikoatferder blant menn som har sex med menn: en pilotrandomisert kontrollert studie
The goal of this clinical trial is to investigate whether receiving chatbot-delivered stage-of-change-tailored online interventions is effective in reducing chemsex among men who have sex with men in Hong Kong. The main question it aims to answer is:
Does chatbot-delivered stage-of-changed online interventions reduce chemsex among men who have sex with men
Eligible participants will be randomly assigned to either the intervention or the control group. The control group will watch one online video introducing chemsex-related knowledge and harm reduction skills per week for 12 weeks. On top of the interventions received by the control group, participants in the intervention group will have access to a chatbot during the 12-week intervention period. The chatbot will deliver 12 weekly episodes of interventions tailored to once's current stage-of-change related to chemsex. The chatbot will also address questions related to chemsex during the intervention period.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Zixin Wang, PhD
- Telefonnummer: +852 22528474
- E-post: wangzx@cuhk.edu.hk
Studiesteder
-
-
-
Hong Kong, Hong Kong
- Rekruttering
- Centre for Health Behaviours Research, JC School of Public Health and Primary Care, the Chinese University of Hong Kong
-
Ta kontakt med:
- Zixin Wang
- Telefonnummer: +852 22528474
- E-post: wangzx@cuhk.edu.hk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Hong Kong men aged at least 18 years
- Able to understand Cantonese
- Had anal intercourse with at least one man within the past six months
- Willingness to provide contact information for follow-up
- Having access to WhatsApp
Exclusion Criteria:
- Self-reported a diagnosis of schizophrenia or bipolar disorder
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention group
Chatbot-delivered interventions and online videos |
Participants will watch one online video introducing chemsex-related knowledge and harm reduction skills per week for 12 weeks. The chatbot will deliver 12 weekly episodes of interventions tailored to once's current stage-of-change related to chemsex. The chatbot will also address questions related to chemsex during the intervention period. |
|
Aktiv komparator: Control group
Online videos only |
Participants will watch one online video introducing chemsex-related knowledge and harm reduction skills per week for 12 weeks. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Presence of chemsex in the past 3 months
Tidsramme: Baseline, after completion of the 12-week intervention (Month 3 or Week 12), and 3 months after completion of the 12-week intervention (Month 6)
|
Presence of chemsex will be measured by a validated 15-item checklist: (1) Methamphetamine ("ice"/"crystal"), (2) GHB/GBL, (3) ketamine, (4) MDMA/ecstasy, (5) cocaine, (6)cannabis, (7) "space oil"/etomidate, (8) mephedrone, (9) 5-methoxy-N, N-diisopropyltryptamine (Foxy), (10) heroin, (11) cough suppressant, (12) sedative/sleeping pills (e.g., zopiclone), (13) erectile dysfunctional drugs (e.g., sildenafil) or (14) poppers (alkyl nitrites) and (15) any other drugs not specified. Participants will be asked whether they had used any of the aforementioned psychoactive substances before or during sexual intercourse in the past 3 months at baseline, after completion of the 12-week intervention (Month 3 or Week 12), and 3 months after completion of the 12-week intervention (Month 6) |
Baseline, after completion of the 12-week intervention (Month 3 or Week 12), and 3 months after completion of the 12-week intervention (Month 6)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ATFMSS393R
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data contains sensitive behaviors.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .